Table 2.
Clinical trials related to the combination therapies of baricitinib and remdesivir for COVID-19 patients
| Study title | Status* | Number enrolled | Phase | Ages eligible for study | Reference | |
|---|---|---|---|---|---|---|
| Baricitinib combinations | Baricitinib in symptomatic patients infected by COVID-19 | Not yet recruiting | 200 |
Phase 2 Phase 3 |
18–85 years (adult, older adult) | NCT04320277 |
| Clinical trial to evaluate efficacy of 3 types of treatment in patients with pneumonia by COVID-19 | Active, not recruiting | 168 | Phase 2 | 18 years and older (adult, older adult) | NCT04346147 | |
| Multi-arm therapeutic study in pre-ICU patients admitted with COVID-19—repurposed drugs (TACTIC-R) | Recruiting | 1167 | Phase 4 | 18 years and older (adult, older adult) | [64], NCT04390464 | |
| Randomized evaluation of COVID-19 Therapy | Recruiting | 45,000 |
Phase 2 Phase 3 |
Child, adult, older adult | [89], NCT04381936 | |
| Baricitinib, placebo and antiviral therapy for the treatment of patients with moderate and severe COVID-19 | Terminated | 6 | Phase 2 | 18 years and older (adult, older adult) | NCT04373044 | |
| Remdesivir combinations | Comparison of remdesivir versus lopinavir/ ritonavir and remdesivir combination in COVID-19 patients | Recruiting | 90 | Phase 4 | 18–80 years (adult, older adult) | NCT04738045 |
| ACTIV-5/big effect trial (BET-B) for the treatment of COVID-19 | Recruiting | 400 | Phase 2 | 18–99 years (adult, older adult) | NCT04583969 | |
| ACTIV-5/big effect trial (BET-A) for the treatment of COVID-19 | Active, not recruiting | 167 | Phase 2 | 18–99 years (adult, older adult) | NCT04583956 | |
| Safety, tolerability and pharmacokinetics of inhaled nanoparticle formulation of remdesivir (GS-5734) and NA-831 (NEUROSIVIR) | Recruiting | 45 | Phase 1 | 21 years to 50 years (adult) | NCT04480333 | |
| Trial to determine the efficacy/safety of plitidepsin vs control in patients with moderate COVID-19 infection (Neptuno) | Recruiting | 609 | Phase 3 | 18 years and older (adult, older adult) | NCT04784559 | |
| Trial of treatments for COVID-19 in hospitalized adults (DisCoVeRy) | Recruiting | 2416 | Phase 3 | 18 years and older (adult, older adult) | [18], NCT04315948 | |
| Adaptive COVID-19 Treatment Trial 3 (ACTT-3) | Completed | 969 | Phase 3 | 18 years and older (adult, older adult) | NCT04492475 | |
| Study to evaluate the efficacy and safety of remdesivir in participants with severely reduced kidney function who Are hospitalized for coronavirus disease 2019 (COVID-19) (REDPINE) | Recruiting | 1116 | Phase 3 | 12 years and older (child, adult, older adult) | NCT04745351 | |
| INF-β 1B and remdesivir for COVID-19 | Recruiting | 100 | Phase 2 | 18 years and older (adult, older adult) | NCT04647695 | |
| Study of merimepodib in combination with remdesivir in adult patients with advanced COVID-19 | Terminated | 44 | Phase 2 | 18 years and older (adult, older adult) | NCT04410354 | |
| Antiviral activity and safety of remdesivir in Bangladeshi patients with severe corona virus disease (COVID-19) | Completed | 60 | Phase 2 | 18 years and older (adult, older adult) | [90], NCT04596839 | |
| Investigational treatments for COVID-19 in tertiary care hospital of Pakistan | Completed | 600 | Not applicable | 18 years to 90 years (adult, older adult) | NCT04492501 | |
| A study to evaluate the efficacy and safety of remdesivir plus tocilizumab compared with remdesivir plus placebo in hospitalized participants with severe COVID-19 pneumonia (REMDACTA) | Completed | 649 | Phase 3 | 12 years and older (child, adult, older adult) | NCT04409262 | |
| Baricitinib plus Remdesivir | Efficacy of remdesivir and baricitinib for the treatment of severe COVID-19 patients | Recruiting | 150 | Phase 3 | Child, adult and older adult | NCT04693026 |
| Adaptive COVID-19 treatment trial 2 (ACTT-2) | Completed | 1033 | Phase 3 | 18 years to 99 years (adult, older adult) | [27], NCT04401579 | |
| Adaptive COVID-19 treatment trial 4 (ACTT-4) | Active, not recruiting | 1010 | Phase 3 | 18 years to 99 years (adult, older adult) | NCT04640168 | |
| Factorial randomized trial of remdesivir and baricitinib plus dexamethasone for COVID-19 (the AMMURAVID Trial) (AMMURAVID) | Not yet recruiting | 4000 | Phase 3 | 18 years and older (adult, older adult) | NCT04832880 | |
*Please refer to https://clinicaltrials.gov/ for more details